Regeneron Pharmaceuticals Inc

Financials

Panoramica Estratto Conto Statistiche Dividendi

Flusso di cassa derivante dalle attività operative 1.26 B1.05 B1.14 B1.62 B1.17 B 4.98 B Flussi di cassa derivanti dalle attività di investimento 350.6 M647.5 M-1.09 B-402.9 M220.3 M -629.1 M Liquidità derivante dalle attività di finanziamento -1.14 B-1.09 B-1.13 B-717.9 M-780.1 M -3.72 B Liquidità libera 1.06 B815.8 M925.4 M1.42 B922 M 4.08 B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

REGN

Financials

Regeneron Pharmaceuticals Inc

Notizie

Regeneron Boosts Cancer Pipeline Through Telix Collaboration

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

H.C. Wainwright conferma il rating su Telix dopo l’accordo con Regeneron

Regeneron e Telix collaborano su terapie oncologiche radiofarmaceutiche

Piper Sandler conferma rating Overweight su Regeneron a 875$

AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV)

REGN or ILMN: Which Is the Better Value Stock Right Now?

Cantor Fitzgerald conferma rating Overweight su Regeneron a $800

Bernstein SocGen riduce il target di prezzo di Regeneron per il cambiamento nel mix dei ricavi

Regeneron prevede un onere IPR&D di 102 milioni di dollari sui risultati del Q1 2026